Advertisement
Perspective

Why Open Drug Discovery Needs Four Simple Rules for Licensing Data and Models

  • Antony J. Williams mail,

    tony27587@gmail.com

    Affiliation: Royal Society of Chemistry, Wake Forest, North Carolina, United States of America

    X
  • John Wilbanks,

    Affiliation: Consent to Research, Oakland, California, United States of America

    X
  • Sean Ekins

    Affiliation: Collaborations in Chemistry, Fuquay-Varina, North Carolina, United States of America

    X
  • Published: September 27, 2012
  • DOI: 10.1371/journal.pcbi.1002706

About the Authors

Antony J. Williams
Royal Society of Chemistry, Wake Forest, North Carolina, United States of America
John Wilbanks
Consent to Research, Oakland, California, United States of America
Sean Ekins
Collaborations in Chemistry, Fuquay-Varina, North Carolina, United States of America

Corresponding Author

Email: tony27587@gmail.com

Competing Interests

Sean Ekins consults for Collaborative Drug Discovery, Inc. and is on the Board of Directors of the Pistoia Alliance. Antony J. Williams is employed by The Royal Society of Chemistry, which hosts the ChemSpider database discussed in this article. John Wilbanks consults for and sits on the Board of Directors at Sage Bionetworks, which runs an open access database of genomic and health information.